{"ticker": {"uuid": "d96e8cba-a161-4d31-b275-b438b2093ce7", "symbol": "PMCB", "name": "PharmaCyte Biotech Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PharmaCyte Biotech (PMCB) Holds Near Support as Modest Decline Tests Trader Conviction - Gap Down Bounce Plays", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQXy1NSHF2U1RhUkFnLU5LWG5iMlNObjR2VXFtTS10eVZnYXdrM3ctZk50TzRKUk9ySl9VNGNjRGt1SGZGaGc4azl4aWNyS0pWNFRobFQ3cEZOWXpYeWFhay1JUE1ndHZVMUtjV09NT2FQQ3BxVVJ1N2x3N0NJd2FrWUp2RDU1TkwtNDE1a3RfOGsxaVpONjRqWWtSQ1dzYllaSHlsSDZXUlltTklKbUp3eXJpSXBzZEM5bEszLVNYQl9nVnM3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-07T17:31:35+00:00", "published_display": "07 Jul 2026 17:31", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech | DEF 14A: Definitive information statements", "summary": "This document from PharmaCyte Biotech is a DEF 14A filing, which provides definitive information statements. These filings are submitted to the SEC by companies prior to a shareholder meeting to provide shareholders with information regarding matters to be voted upon. It likely c", "url": "https://www.moomoo.com/news/notice/306624017/pharmacyte-biotech-def-14a-definitive-information-statements", "source_name": "Moomoo", "published_at": "2026-07-06T20:40:29", "published_display": "06 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech | SCHEDULE 13G: Others", "summary": "This article provides details of a Schedule 13G filing for PharmaCyte Biotech. Schedule 13G filings are typically used by passive investors who own between 5-20% of a company's stock, indicating significant ownership without intending to influence control.", "url": "https://www.moomoo.com/news/notice/306693895/pharmacyte-biotech-schedule-13g-others", "source_name": "Moomoo", "published_at": "2026-07-04T18:09:42", "published_display": "04 Jul 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of PharmaCyte Biotech, Inc. \u2013 NASDAQ:PMCB", "summary": "This article provides the \"Price to book forward\" for PharmaCyte Biotech, Inc. (NASDAQ:PMCB), as listed on TradingView. It appears to be a financial data snippet rather than an in-depth analysis. The stock market for PMCB is currently closed with no trades.", "url": "https://www.tradingview.com/symbols/NASDAQ-PMCB/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T04:10:03", "published_display": "01 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of PharmaCyte Biotech, Inc. \u2013 NASDAQ:PMCB", "summary": "The article displays the \"Price to sales forward\" metric for PharmaCyte Biotech, Inc. (NASDAQ: PMCB) on TradingView. It appears to be a financial data point for the company, accessible through the platform's market analysis tools. The content includes navigation and footer elemen", "url": "https://www.tradingview.com/symbols/NASDAQ-PMCB/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T20:09:02", "published_display": "27 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of PharmaCyte Biotech, Inc. \u2013 NASDAQ:PMCB", "summary": "The article lists the \"Price to earnings forward\" for PharmaCyte Biotech, Inc. (NASDAQ: PMCB). It appears to be a financial data entry on a trading platform, indicating the value and change of this financial metric, likely for a specific period.", "url": "https://www.tradingview.com/symbols/NASDAQ-PMCB/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:10:03", "published_display": "27 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech Inc (PMCB) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for PharmaCyte Biotech Inc (PMCB), indicating a current risk score of 1.34 and ranking 305 out of 386 in its industry. The company's beta of 0.50 suggests it is less volatile than the overall market. The assessment includes various metrics ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmcb/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-19T07:10:42", "published_display": "19 Jun 2026 07:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech Inc (PMCB) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of PharmaCyte Biotech Inc (PMCB), including a breakdown of major individual and institutional holders as well as different shareholder types. It lists top individual holders like Joshua Silverman and institutional investors such as C", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmcb/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T07:39:52", "published_display": "18 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech Inc (PMCB) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of PharmaCyte Biotech Inc (PMCB), noting its current financial score of 6.98, which ranks 172 out of 389 in the Biotechnology & Medical Research industry. The company's financial status is described as robust, though its operating", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmcb/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T23:10:07", "published_display": "17 Jun 2026 23:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech Inc (PMCB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article for PharmaCyte Biotech Inc (PMCB) on TradingKey discusses the company's revenue breakdown. However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page provides gener", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmcb/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:29", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech Inc (PMCB) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of PharmaCyte Biotech Inc (PMCB) focusing on its dividend and stock split history. It indicates that the company has distributed $0.00 in dividends over the past five years and has no historical stock split data. The current stock price, market c", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmcb/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:29", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech Inc (PMCB) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of PharmaCyte Biotech Inc (PMCB), outlining its current price momentum, support and resistance levels, and signals from various technical indicators and moving averages. As of June 17, 2026, PMCB's price momentum score is 6.86, trading b", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmcb/technical", "source_name": "TradingKey", "published_at": "2026-06-16T22:40:27", "published_display": "16 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech Inc (PMCB) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for PharmaCyte Biotech Inc (PMCB), indicating that no earnings forecast score is currently available for the company. It notes that the Biotechnology & Medical Research industry's average score is 8.13. The company has not yet disclosed ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmcb/earnings", "source_name": "TradingKey", "published_at": "2026-06-16T22:40:27", "published_display": "16 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech Inc (PMCB) Institutional Confidence", "summary": "PharmaCyte Biotech Inc (PMCB) has an institutional shareholding score of 3.00, placing it 193 out of 388 in the Biotechnology & Medical Research industry. The institutional shareholding proportion recently increased by 132.81% quarter-over-quarter, reaching 9.99%. James Simons is", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmcb/sentiment", "source_name": "TradingKey", "published_at": "2026-06-16T10:39:29", "published_display": "16 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech (Nasdaq:PMCB) - Stock Analysis", "summary": "This extensive stock analysis of PharmaCyte Biotech (Nasdaq: PMCB) provides an overview of the company's financials, performance, and recent news. The biotechnology company, focused on developing cellular therapies for cancer, currently has a small market cap of US$8.2m and no re", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pmcb/pharmacyte-biotech", "source_name": "Simply Wall Street", "published_at": "2026-06-15T09:10:57", "published_display": "15 Jun 2026 09:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMCB Technical Analysis & Stock Price Forecast", "summary": "This article provides a technical analysis and stock price forecast for PharmaCyte Biotech Inc (PMCB), concluding with a \"Strong Sell\" consensus based on various technical indicators and moving averages. While some oscillators like the Stochastic Oscillator show buy signals, key ", "url": "https://intellectia.ai/en/stock/PMCB/technical", "source_name": "Intellectia AI", "published_at": "2026-06-08T06:40:00", "published_display": "08 Jun 2026 06:40", "sentiment": "negative", "sentiment_pct": 13, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech (PMCB) Rises 3.19%: Approaching Resistance Zone Amid Biotech Sector Focus - Sector Leader Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNS2xvNHFheklLTU9qR3BmRmtIY1NUTVNuYllEcHhhTmloUF8yNHJmczBKdVZMeEhEYlltcE1heTVoNjZaUXlWSE1QMTlQd1F1YmtFWVBicG1XSDVoMm5meEE5TVlJaVQzQWlBdG1uNWs1NDM4SkF5WnJZUnNSbVdPbDFQejRNcWRjNlVDQUU0WWNQMGp6MXpWRXN1U1JEN1gzUm1YbVZ4T0RTWExOWGNBMzFKR0F0akl3ek9uY0FYWXVkWWx0MVFySA?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech (PMCB) Slips 3.3% as Stock Nears Critical Support at $0.79 - Fundamental Weighted", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxONlF4TGVnRjZwcjhXNGFjNVFfZnotclFJWHp3QXdOMFh0MG9ObzV6dUlIVktIY2Y3M0hPbHBOT3FCeHBKeWpocml6WXJUMjc4WDRuZ2NGamIySVU5Mlg0d2xxTnFocjZ5T2d0R0VkUERiZDJJdDdKMHNMdllXdmFQT0Z4UjUyRHoxUTkyLUJNNHk5MmJaRURZeExTeEpRSWhGZVlHZFltOTBWYXZaZ0dZc0R1Smc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMCB - PharmaCyte Biotech Inc Stock Price and Quote", "summary": "This page provides a detailed overview of PharmaCyte Biotech Inc. (PMCB) stock, including its current price, market performance, financial metrics, and recent news. It also lists key insider transactions and provides company information, highlighting its focus on developing treat", "url": "https://finviz.com/stock?t=PMCB", "source_name": "Finviz", "published_at": "2026-05-26T12:40:06", "published_display": "26 May 2026 12:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech (PMCB) Edges Higher: Support-Holding Action at $0.81 - Bullish Sentiment", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQMVRIVFQ0MHNpOXp6V1hnRlBsSEZRaG4tVnV1QV9zckY2elpQdkN0SHQtbjZKU01nbXJSSjl2MnVYY19wLXlRSzVTbU5TUW9ndUZpZ0w4MF92YU5JeGhKSzBydXlLZUxZc0xOYWU4RkxtNWo4a3UzMzNXMHlfNGJOdGlwa0JmUV9FaHNEOGczYmRqWFZoZThEY3puX2dScTJ0VHotWEY2akx1WV9XVWc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TradingKey", "summary": "This page displays market data for PharmaCyte Biotech Inc. (PMCB), including its current stock price, market capitalization, and recent performance. The platform, TradingKey, provides financial information, analysis tools, and market news, and offers disclaimers regarding investm", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmcb/comments", "source_name": "TradingKey", "published_at": "2026-05-15T10:39:50", "published_display": "15 May 2026 10:39", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PMCB SEC Filings - Pharmacyte Biotech Inc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Pharmacyte Biotech (PMCB) SEC filings, including 10-K, 10-Q, and 8-K forms, alongside AI-generated summaries and impact analyses. Recent filings cover topics such as a proposed reverse stock split, insider ownership updates with war", "url": "https://www.stocktitan.net/sec-filings/PMCB/page-2.html", "source_name": "Stock Titan", "published_at": "2026-04-24T18:39:24", "published_display": "24 Apr 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PharmaCyte Biotech (PMCB) director awarded 119,170 stock options at $0.67", "summary": "PharmaCyte Biotech director Jonathan Schechter was granted 119,170 stock options with an exercise price of $0.67 and an expiration date of March 30, 2036. This award serves as compensation and vests fully at the company's next annual stockholder meeting, contingent on his continu", "url": "https://www.stocktitan.net/sec-filings/PMCB/form-4-pharma-cyte-biotech-inc-insider-trading-activity-744eb4cc5266.html", "source_name": "Stock Titan", "published_at": "2026-04-08T05:09:31", "published_display": "08 Apr 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at PharmaCyte Biotech (PMCB) gets 119,170 options", "summary": "PharmaCyte Biotech director Wayne Remell Walker has been granted 119,170 stock options with an exercise price of $0.67 per share, expiring on March 30, 2036. The options will fully vest on the date of the company's next annual meeting, provided Mr. Walker continues his service. T", "url": "https://www.stocktitan.net/sec-filings/PMCB/form-4-pharma-cyte-biotech-inc-insider-trading-activity-d6bc16a92e6e.html", "source_name": "Stock Titan", "published_at": "2026-04-02T22:10:44", "published_display": "02 Apr 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech (PMCB) director receives 119,170 stock options at $0.67", "summary": "PharmaCyte Biotech director Michael M. Abecassis was granted 119,170 stock options with an exercise price of $0.67 per share, expiring on March 30, 2036. These options will fully vest on the date of the company's next annual meeting, contingent on his continued service. This Form", "url": "https://www.stocktitan.net/sec-filings/PMCB/form-4-pharma-cyte-biotech-inc-insider-trading-activity-43fcd76a1236.html", "source_name": "Stock Titan", "published_at": "2026-04-02T22:10:43", "published_display": "02 Apr 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Weinstein receives 119,170 stock options at PharmaCyte Biotech (PMCB)", "summary": "PharmaCyte Biotech, Inc. reported that director Robert Weinstein received a grant of 119,170 stock options with an exercise price of $0.67 per share. These options, which expire on March 30, 2036, will vest in full upon the date of the company's next annual meeting of stockholder", "url": "https://www.stocktitan.net/sec-filings/PMCB/form-4-pharma-cyte-biotech-inc-insider-trading-activity-5580e3e4fc29.html", "source_name": "Stock Titan", "published_at": "2026-04-02T22:10:43", "published_display": "02 Apr 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech Shareholders Approve Governance and Equity Actions", "summary": "PharmaCyte Biotech shareholders approved key governance and equity actions during their annual meeting on March 30, 2026. These actions included the election of directors, ratification of their independent auditor, advisory approval of executive compensation, authorization for a ", "url": "https://www.tipranks.com/news/company-announcements/pharmacyte-biotech-shareholders-approve-governance-and-equity-actions", "source_name": "TipRanks", "published_at": "2026-04-02T21:10:43", "published_display": "02 Apr 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech (PMCB) wins approval for reverse split range and 2M new plan shares", "summary": "PharmaCyte Biotech (PMCB) shareholders approved all five proposals at their annual meeting, including an amendment to the 2022 Equity Incentive Plan to increase shares available for awards by 2,000,000. They also granted the board discretionary authority to implement a reverse st", "url": "https://www.stocktitan.net/sec-filings/PMCB/8-k-pharma-cyte-biotech-inc-reports-material-event-bcd3f65085a6.html", "source_name": "Stock Titan", "published_at": "2026-04-02T20:10:44", "published_display": "02 Apr 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PharmaCyte Biotech 10-Q: $0.0M Revenue, $(0.17) EPS (Q3), $(2.41) EPS (YTD)", "summary": "PharmaCyte Biotech reported no revenue for the three and nine months ended January 31, 2026, with a significant per-share loss of $(0.17) for the quarter and $(2.41) year-to-date. The company is actively engaged with the FDA regarding a clinical hold for pancreatic cancer and is ", "url": "https://www.tradingview.com/news/tradingview:f405c44e5530f:0-pharmacyte-biotech-10-q-0-0m-revenue-0-17-eps-q3-2-41-eps-ytd/", "source_name": "TradingView", "published_at": "2026-03-17T19:39:56", "published_display": "17 Mar 2026 19:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech (PMCB) seeks reverse split, equity plan boost at 2026 meeting", "summary": "PharmaCyte Biotech (PMCB) will hold a virtual annual shareholder meeting on March 30, 2026, to vote on key corporate matters including the election of five directors, ratification of CBIZ CPAs P.C. as auditor, and an advisory vote on executive compensation. The company is also pr", "url": "https://www.stocktitan.net/sec-filings/PMCB/def-14a-pharma-cyte-biotech-inc-definitive-proxy-statement-b7c03f235b5a.html", "source_name": "Stock Titan", "published_at": "2026-03-10T08:09:12", "published_display": "10 Mar 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMCB Should I Buy", "summary": "An analysis of PharmaCyte Biotech Inc (PMCB) suggests it is not a strong buy opportunity for beginner, long-term investors. Despite some improvements in financial losses year-over-year, the company shows no revenue growth, weak overall financials, and mixed technical indicators l", "url": "https://intellectia.ai/en/stock/PMCB/should-i-buy", "source_name": "Intellectia AI", "published_at": "2026-02-28T04:51:27", "published_display": "28 Feb 2026 04:51", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech (PMCB) seeks reverse split and 2M share plan boost at virtual meeting", "summary": "PharmaCyte Biotech (PMCB) is holding a virtual annual meeting on March 30, 2026, to vote on several key proposals, including the election of five directors, ratification of CBIZ CPAs P.C. as auditor, and advisory approval of executive compensation. Critically, the company seeks s", "url": "https://www.stocktitan.net/sec-filings/PMCB/pre-14a-pharma-cyte-biotech-inc-preliminary-proxy-statement-1e11eae4a2a1.html", "source_name": "Stock Titan", "published_at": "2026-02-27T21:52:25", "published_display": "27 Feb 2026 21:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMCB Financials: Income Statement, Balance Sheet & Cash Flow", "summary": "This article provides a detailed financial overview of Pharmacyte Biotech Inc (PMCB) for fiscal year 2025, derived from SEC filings. It includes key financial metrics such as revenue, net income, EPS, cash & debt, and share buybacks, alongside the company's income statement, bala", "url": "https://www.stocktitan.net/financials/PMCB/", "source_name": "Stock Titan", "published_at": "2026-02-25T02:52:25", "published_display": "25 Feb 2026 02:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharmacyte Biotech CEO Silverman buys $80k in shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNdFFTeF94bVdRSjBMQjF2N0dGdF92N1M1YUVZbW9zNnMyNVhvREZzeEoybXdNdzA4Mjc3bE56a2V6LS1NTzJsQlVLWDNlREZlWXJhWWl1Y1hHVC1EVk1JajlaRkQ0WnJDNWs3ODZNbHM3WXlKWl9TZXBDMGdra1QxdWdPV1BIdVhjdU81a1hicjJfMU5tUURvZzdxMWpfbHdSX2xVSEUyZU5YNXBlMDBHdkRWWlNLam8?oc=5", "source_name": "Investing.com", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech: Is Growth Here to Stay?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPMzdoOHF6ejlacjFUZkJ2YWhFbDRrTzFwaFV4SVpvaFI2NXJDNXJqMzVza0J3dTlOYXItNjJ1OGFLczgxZGZVbEZiZFFid1p3bnVCTWkwazlKbjFXeGZGUEluYVQ0cEpRdjREMFZBR19aeGJqbWNMMEFyQTZWcDVUTg?oc=5", "source_name": "StocksToTrade", "published_at": "2025-12-04T08:00:00+00:00", "published_display": "04 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNSHlwY1BPbDhxcFFibl9jRmJtek9rVGtqS09LcERzN0NuMUx4SExxbzdHeWlLSUlSWllueVpXby0xdjRDWU5aMkFhS1hxc1lCWE9wVnhkcjNYVzdWTk9QY05OX1RWWFdKOUxFYW52QkpBU1FONE5OdzRBTzFSUFByZVVoVUlJbjk1WGZZazhxaEZQSlI4ZXNqSDZUb0Z0RFJXUEZQbHU5Z21uOTgzbGc?oc=5", "source_name": "Investing News Network", "published_at": "2025-09-12T07:27:26+00:00", "published_display": "12 Sep 2025 07:27", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharmacyte Biotech (PMCB) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1raVRUZ3BhdTNrUXBpVUQ0OEhJM2FtdWR5SUhtb2RoVkhTUFFUU3N6dkZEMUVoZDE2Q2NIbEY3d1lNVmh3YWw1XzJnNXp1RERkVnVN?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:15:22+00:00", "published_display": "25 Apr 2025 00:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Femasys secures nearly $7M in funding from PharmaCyte", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPMXRkUVp0OEp4bGVQcmJUUFN2Rkc1aElGMUhaejNTVjlIdjdGVEVjM0l5ejhXNnZMcDBwbTNNcG1QZlZhYURvOEQ1cGNOaURhRC1Wd2pOVktneGk3TS10VWkyN3owaEtCV2toeXJ5dGlmRTczZHg3cnFFTEUzVTdta0I5VklDZE0?oc=5", "source_name": "MassDevice", "published_at": "2023-11-15T08:00:00+00:00", "published_display": "15 Nov 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech Inc (PMCB) Share Price Today | PharmaCyte Biotech Inc (PMCB) Live NSE/BSE", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQbE9sZmpzRVNOb0EyZWpXMkZZUzQxMnBQVWNMRzV6WTBaZ3JiSUZ5RjdZQl96dEdUZEpDOW94Y0gydnoyRFBqb1h0Nmo3Wngwek1zZ1RSSmM4WC1kNmd6SFBKeEljZnl0WmxJdEk2b0p5VW13WnhvTGdsckpLQzFPanQxZWU?oc=5", "source_name": "Value Research", "published_at": "2023-01-11T15:04:52+00:00", "published_display": "11 Jan 2023 15:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After Nasdaq Uplisting, PharmaCyte Biotech Looks Ready to Rumble", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOMmtZUmVXb1BuOXhBSUtkWmNoaDJwUE9LdTVBUE1QS0dfWHJvbVg4dWRiSkZ4UkpqejR0dFVCVXRONS12VUpLbl9uT3gzUTVLRnA4eHplSmVxbzZ5bmd6SnJLa2x4ZHRUeEExdmJrbG5BZ1Nadk82X1Z1aFVyRzJSMDVKb2Q2NlNpZzlxQ0pwWV9DUzFEaFNFdDdnNWJLZy1aSlJRNURJdXRpdw?oc=5", "source_name": "entrepreneur.com", "published_at": "2021-09-07T07:00:00+00:00", "published_display": "07 Sep 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMCB Stock Price and Chart \u2014 NASDAQ:PMCB", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1kR0tzbEZqR19pVEM3Q0tYWFUtV2FONmxlclhZVnNHUnpEZEVEMVA0Q3dxVlJ5a1dpNVU2Tm9UanJLMmh4N3NlelVUMjQ2N2xNOS1sNVg3ZU9jMXhR?oc=5", "source_name": "TradingView", "published_at": "2021-08-11T00:30:46+00:00", "published_display": "11 Aug 2021 00:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharmacyte Biotech (PMCB) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE84dHpsSFI5MU9IOGVuUXhWaElSb0hxNnVuVXZ2TUxRVF9uN1Q4SDdydXhBX2F2RHk1NDFQUGNuQTVHYTRqZm96Q0VPVGZwZw?oc=5", "source_name": "Stock Titan", "published_at": "2020-12-14T15:48:52+00:00", "published_display": "14 Dec 2020 15:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "PharmaCyte Biotech (PMCB) Holds Near Support as Modest Decline Tests Trader Conviction - Gap Down Bounce Plays", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQXy1NSHF2U1RhUkFnLU5LWG5iMlNObjR2VXFtTS10eVZnYXdrM3ctZk50TzRKUk9ySl9VNGNjRGt1SGZGaGc4azl4aWNyS0pWNFRobFQ3cEZOWXpYeWFhay1JUE1ndHZVMUtjV09NT2FQQ3BxVVJ1N2x3N0NJd2FrWUp2RDU1TkwtNDE1a3RfOGsxaVpONjRqWWtSQ1dzYllaSHlsSDZXUlltTklKbUp3eXJpSXBzZEM5bEszLVNYQl9nVnM3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-07T17:31:35+00:00", "published_display": "07 Jul 2026 17:31", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech | DEF 14A: Definitive information statements", "summary": "This document from PharmaCyte Biotech is a DEF 14A filing, which provides definitive information statements. These filings are submitted to the SEC by companies prior to a shareholder meeting to provide shareholders with information regarding matters to be voted upon. It likely c", "url": "https://www.moomoo.com/news/notice/306624017/pharmacyte-biotech-def-14a-definitive-information-statements", "source_name": "Moomoo", "published_at": "2026-07-06T20:40:29", "published_display": "06 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech | SCHEDULE 13G: Others", "summary": "This article provides details of a Schedule 13G filing for PharmaCyte Biotech. Schedule 13G filings are typically used by passive investors who own between 5-20% of a company's stock, indicating significant ownership without intending to influence control.", "url": "https://www.moomoo.com/news/notice/306693895/pharmacyte-biotech-schedule-13g-others", "source_name": "Moomoo", "published_at": "2026-07-04T18:09:42", "published_display": "04 Jul 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of PharmaCyte Biotech, Inc. \u2013 NASDAQ:PMCB", "summary": "This article provides the \"Price to book forward\" for PharmaCyte Biotech, Inc. (NASDAQ:PMCB), as listed on TradingView. It appears to be a financial data snippet rather than an in-depth analysis. The stock market for PMCB is currently closed with no trades.", "url": "https://www.tradingview.com/symbols/NASDAQ-PMCB/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T04:10:03", "published_display": "01 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of PharmaCyte Biotech, Inc. \u2013 NASDAQ:PMCB", "summary": "The article displays the \"Price to sales forward\" metric for PharmaCyte Biotech, Inc. (NASDAQ: PMCB) on TradingView. It appears to be a financial data point for the company, accessible through the platform's market analysis tools. The content includes navigation and footer elemen", "url": "https://www.tradingview.com/symbols/NASDAQ-PMCB/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T20:09:02", "published_display": "27 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of PharmaCyte Biotech, Inc. \u2013 NASDAQ:PMCB", "summary": "The article lists the \"Price to earnings forward\" for PharmaCyte Biotech, Inc. (NASDAQ: PMCB). It appears to be a financial data entry on a trading platform, indicating the value and change of this financial metric, likely for a specific period.", "url": "https://www.tradingview.com/symbols/NASDAQ-PMCB/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:10:03", "published_display": "27 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech Inc (PMCB) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for PharmaCyte Biotech Inc (PMCB), indicating a current risk score of 1.34 and ranking 305 out of 386 in its industry. The company's beta of 0.50 suggests it is less volatile than the overall market. The assessment includes various metrics ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmcb/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-19T07:10:42", "published_display": "19 Jun 2026 07:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech Inc (PMCB) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of PharmaCyte Biotech Inc (PMCB), including a breakdown of major individual and institutional holders as well as different shareholder types. It lists top individual holders like Joshua Silverman and institutional investors such as C", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmcb/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T07:39:52", "published_display": "18 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech Inc (PMCB) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of PharmaCyte Biotech Inc (PMCB), noting its current financial score of 6.98, which ranks 172 out of 389 in the Biotechnology & Medical Research industry. The company's financial status is described as robust, though its operating", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmcb/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T23:10:07", "published_display": "17 Jun 2026 23:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech Inc (PMCB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article for PharmaCyte Biotech Inc (PMCB) on TradingKey discusses the company's revenue breakdown. However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page provides gener", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmcb/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:29", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech Inc (PMCB) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of PharmaCyte Biotech Inc (PMCB) focusing on its dividend and stock split history. It indicates that the company has distributed $0.00 in dividends over the past five years and has no historical stock split data. The current stock price, market c", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmcb/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:29", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech Inc (PMCB) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of PharmaCyte Biotech Inc (PMCB), outlining its current price momentum, support and resistance levels, and signals from various technical indicators and moving averages. As of June 17, 2026, PMCB's price momentum score is 6.86, trading b", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmcb/technical", "source_name": "TradingKey", "published_at": "2026-06-16T22:40:27", "published_display": "16 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech Inc (PMCB) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for PharmaCyte Biotech Inc (PMCB), indicating that no earnings forecast score is currently available for the company. It notes that the Biotechnology & Medical Research industry's average score is 8.13. The company has not yet disclosed ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmcb/earnings", "source_name": "TradingKey", "published_at": "2026-06-16T22:40:27", "published_display": "16 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech Inc (PMCB) Institutional Confidence", "summary": "PharmaCyte Biotech Inc (PMCB) has an institutional shareholding score of 3.00, placing it 193 out of 388 in the Biotechnology & Medical Research industry. The institutional shareholding proportion recently increased by 132.81% quarter-over-quarter, reaching 9.99%. James Simons is", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmcb/sentiment", "source_name": "TradingKey", "published_at": "2026-06-16T10:39:29", "published_display": "16 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech (Nasdaq:PMCB) - Stock Analysis", "summary": "This extensive stock analysis of PharmaCyte Biotech (Nasdaq: PMCB) provides an overview of the company's financials, performance, and recent news. The biotechnology company, focused on developing cellular therapies for cancer, currently has a small market cap of US$8.2m and no re", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pmcb/pharmacyte-biotech", "source_name": "Simply Wall Street", "published_at": "2026-06-15T09:10:57", "published_display": "15 Jun 2026 09:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMCB Technical Analysis & Stock Price Forecast", "summary": "This article provides a technical analysis and stock price forecast for PharmaCyte Biotech Inc (PMCB), concluding with a \"Strong Sell\" consensus based on various technical indicators and moving averages. While some oscillators like the Stochastic Oscillator show buy signals, key ", "url": "https://intellectia.ai/en/stock/PMCB/technical", "source_name": "Intellectia AI", "published_at": "2026-06-08T06:40:00", "published_display": "08 Jun 2026 06:40", "sentiment": "negative", "sentiment_pct": 13, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech (PMCB) Rises 3.19%: Approaching Resistance Zone Amid Biotech Sector Focus - Sector Leader Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNS2xvNHFheklLTU9qR3BmRmtIY1NUTVNuYllEcHhhTmloUF8yNHJmczBKdVZMeEhEYlltcE1heTVoNjZaUXlWSE1QMTlQd1F1YmtFWVBicG1XSDVoMm5meEE5TVlJaVQzQWlBdG1uNWs1NDM4SkF5WnJZUnNSbVdPbDFQejRNcWRjNlVDQUU0WWNQMGp6MXpWRXN1U1JEN1gzUm1YbVZ4T0RTWExOWGNBMzFKR0F0akl3ek9uY0FYWXVkWWx0MVFySA?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech (PMCB) Slips 3.3% as Stock Nears Critical Support at $0.79 - Fundamental Weighted", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxONlF4TGVnRjZwcjhXNGFjNVFfZnotclFJWHp3QXdOMFh0MG9ObzV6dUlIVktIY2Y3M0hPbHBOT3FCeHBKeWpocml6WXJUMjc4WDRuZ2NGamIySVU5Mlg0d2xxTnFocjZ5T2d0R0VkUERiZDJJdDdKMHNMdllXdmFQT0Z4UjUyRHoxUTkyLUJNNHk5MmJaRURZeExTeEpRSWhGZVlHZFltOTBWYXZaZ0dZc0R1Smc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMCB - PharmaCyte Biotech Inc Stock Price and Quote", "summary": "This page provides a detailed overview of PharmaCyte Biotech Inc. (PMCB) stock, including its current price, market performance, financial metrics, and recent news. It also lists key insider transactions and provides company information, highlighting its focus on developing treat", "url": "https://finviz.com/stock?t=PMCB", "source_name": "Finviz", "published_at": "2026-05-26T12:40:06", "published_display": "26 May 2026 12:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech (PMCB) Edges Higher: Support-Holding Action at $0.81 - Bullish Sentiment", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQMVRIVFQ0MHNpOXp6V1hnRlBsSEZRaG4tVnV1QV9zckY2elpQdkN0SHQtbjZKU01nbXJSSjl2MnVYY19wLXlRSzVTbU5TUW9ndUZpZ0w4MF92YU5JeGhKSzBydXlLZUxZc0xOYWU4RkxtNWo4a3UzMzNXMHlfNGJOdGlwa0JmUV9FaHNEOGczYmRqWFZoZThEY3puX2dScTJ0VHotWEY2akx1WV9XVWc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TradingKey", "summary": "This page displays market data for PharmaCyte Biotech Inc. (PMCB), including its current stock price, market capitalization, and recent performance. The platform, TradingKey, provides financial information, analysis tools, and market news, and offers disclaimers regarding investm", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmcb/comments", "source_name": "TradingKey", "published_at": "2026-05-15T10:39:50", "published_display": "15 May 2026 10:39", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMCB SEC Filings - Pharmacyte Biotech Inc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Pharmacyte Biotech (PMCB) SEC filings, including 10-K, 10-Q, and 8-K forms, alongside AI-generated summaries and impact analyses. Recent filings cover topics such as a proposed reverse stock split, insider ownership updates with war", "url": "https://www.stocktitan.net/sec-filings/PMCB/page-2.html", "source_name": "Stock Titan", "published_at": "2026-04-24T18:39:24", "published_display": "24 Apr 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech (PMCB) director awarded 119,170 stock options at $0.67", "summary": "PharmaCyte Biotech director Jonathan Schechter was granted 119,170 stock options with an exercise price of $0.67 and an expiration date of March 30, 2036. This award serves as compensation and vests fully at the company's next annual stockholder meeting, contingent on his continu", "url": "https://www.stocktitan.net/sec-filings/PMCB/form-4-pharma-cyte-biotech-inc-insider-trading-activity-744eb4cc5266.html", "source_name": "Stock Titan", "published_at": "2026-04-08T05:09:31", "published_display": "08 Apr 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at PharmaCyte Biotech (PMCB) gets 119,170 options", "summary": "PharmaCyte Biotech director Wayne Remell Walker has been granted 119,170 stock options with an exercise price of $0.67 per share, expiring on March 30, 2036. The options will fully vest on the date of the company's next annual meeting, provided Mr. Walker continues his service. T", "url": "https://www.stocktitan.net/sec-filings/PMCB/form-4-pharma-cyte-biotech-inc-insider-trading-activity-d6bc16a92e6e.html", "source_name": "Stock Titan", "published_at": "2026-04-02T22:10:44", "published_display": "02 Apr 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech (PMCB) director receives 119,170 stock options at $0.67", "summary": "PharmaCyte Biotech director Michael M. Abecassis was granted 119,170 stock options with an exercise price of $0.67 per share, expiring on March 30, 2036. These options will fully vest on the date of the company's next annual meeting, contingent on his continued service. This Form", "url": "https://www.stocktitan.net/sec-filings/PMCB/form-4-pharma-cyte-biotech-inc-insider-trading-activity-43fcd76a1236.html", "source_name": "Stock Titan", "published_at": "2026-04-02T22:10:43", "published_display": "02 Apr 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Weinstein receives 119,170 stock options at PharmaCyte Biotech (PMCB)", "summary": "PharmaCyte Biotech, Inc. reported that director Robert Weinstein received a grant of 119,170 stock options with an exercise price of $0.67 per share. These options, which expire on March 30, 2036, will vest in full upon the date of the company's next annual meeting of stockholder", "url": "https://www.stocktitan.net/sec-filings/PMCB/form-4-pharma-cyte-biotech-inc-insider-trading-activity-5580e3e4fc29.html", "source_name": "Stock Titan", "published_at": "2026-04-02T22:10:43", "published_display": "02 Apr 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech Shareholders Approve Governance and Equity Actions", "summary": "PharmaCyte Biotech shareholders approved key governance and equity actions during their annual meeting on March 30, 2026. These actions included the election of directors, ratification of their independent auditor, advisory approval of executive compensation, authorization for a ", "url": "https://www.tipranks.com/news/company-announcements/pharmacyte-biotech-shareholders-approve-governance-and-equity-actions", "source_name": "TipRanks", "published_at": "2026-04-02T21:10:43", "published_display": "02 Apr 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech (PMCB) wins approval for reverse split range and 2M new plan shares", "summary": "PharmaCyte Biotech (PMCB) shareholders approved all five proposals at their annual meeting, including an amendment to the 2022 Equity Incentive Plan to increase shares available for awards by 2,000,000. They also granted the board discretionary authority to implement a reverse st", "url": "https://www.stocktitan.net/sec-filings/PMCB/8-k-pharma-cyte-biotech-inc-reports-material-event-bcd3f65085a6.html", "source_name": "Stock Titan", "published_at": "2026-04-02T20:10:44", "published_display": "02 Apr 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech 10-Q: $0.0M Revenue, $(0.17) EPS (Q3), $(2.41) EPS (YTD)", "summary": "PharmaCyte Biotech reported no revenue for the three and nine months ended January 31, 2026, with a significant per-share loss of $(0.17) for the quarter and $(2.41) year-to-date. The company is actively engaged with the FDA regarding a clinical hold for pancreatic cancer and is ", "url": "https://www.tradingview.com/news/tradingview:f405c44e5530f:0-pharmacyte-biotech-10-q-0-0m-revenue-0-17-eps-q3-2-41-eps-ytd/", "source_name": "TradingView", "published_at": "2026-03-17T19:39:56", "published_display": "17 Mar 2026 19:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech (PMCB) seeks reverse split, equity plan boost at 2026 meeting", "summary": "PharmaCyte Biotech (PMCB) will hold a virtual annual shareholder meeting on March 30, 2026, to vote on key corporate matters including the election of five directors, ratification of CBIZ CPAs P.C. as auditor, and an advisory vote on executive compensation. The company is also pr", "url": "https://www.stocktitan.net/sec-filings/PMCB/def-14a-pharma-cyte-biotech-inc-definitive-proxy-statement-b7c03f235b5a.html", "source_name": "Stock Titan", "published_at": "2026-03-10T08:09:12", "published_display": "10 Mar 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMCB Should I Buy", "summary": "An analysis of PharmaCyte Biotech Inc (PMCB) suggests it is not a strong buy opportunity for beginner, long-term investors. Despite some improvements in financial losses year-over-year, the company shows no revenue growth, weak overall financials, and mixed technical indicators l", "url": "https://intellectia.ai/en/stock/PMCB/should-i-buy", "source_name": "Intellectia AI", "published_at": "2026-02-28T04:51:27", "published_display": "28 Feb 2026 04:51", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech (PMCB) seeks reverse split and 2M share plan boost at virtual meeting", "summary": "PharmaCyte Biotech (PMCB) is holding a virtual annual meeting on March 30, 2026, to vote on several key proposals, including the election of five directors, ratification of CBIZ CPAs P.C. as auditor, and advisory approval of executive compensation. Critically, the company seeks s", "url": "https://www.stocktitan.net/sec-filings/PMCB/pre-14a-pharma-cyte-biotech-inc-preliminary-proxy-statement-1e11eae4a2a1.html", "source_name": "Stock Titan", "published_at": "2026-02-27T21:52:25", "published_display": "27 Feb 2026 21:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMCB Financials: Income Statement, Balance Sheet & Cash Flow", "summary": "This article provides a detailed financial overview of Pharmacyte Biotech Inc (PMCB) for fiscal year 2025, derived from SEC filings. It includes key financial metrics such as revenue, net income, EPS, cash & debt, and share buybacks, alongside the company's income statement, bala", "url": "https://www.stocktitan.net/financials/PMCB/", "source_name": "Stock Titan", "published_at": "2026-02-25T02:52:25", "published_display": "25 Feb 2026 02:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharmacyte Biotech CEO Silverman buys $80k in shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNdFFTeF94bVdRSjBMQjF2N0dGdF92N1M1YUVZbW9zNnMyNVhvREZzeEoybXdNdzA4Mjc3bE56a2V6LS1NTzJsQlVLWDNlREZlWXJhWWl1Y1hHVC1EVk1JajlaRkQ0WnJDNWs3ODZNbHM3WXlKWl9TZXBDMGdra1QxdWdPV1BIdVhjdU81a1hicjJfMU5tUURvZzdxMWpfbHdSX2xVSEUyZU5YNXBlMDBHdkRWWlNLam8?oc=5", "source_name": "Investing.com", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech: Is Growth Here to Stay?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPMzdoOHF6ejlacjFUZkJ2YWhFbDRrTzFwaFV4SVpvaFI2NXJDNXJqMzVza0J3dTlOYXItNjJ1OGFLczgxZGZVbEZiZFFid1p3bnVCTWkwazlKbjFXeGZGUEluYVQ0cEpRdjREMFZBR19aeGJqbWNMMEFyQTZWcDVUTg?oc=5", "source_name": "StocksToTrade", "published_at": "2025-12-04T08:00:00+00:00", "published_display": "04 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNSHlwY1BPbDhxcFFibl9jRmJtek9rVGtqS09LcERzN0NuMUx4SExxbzdHeWlLSUlSWllueVpXby0xdjRDWU5aMkFhS1hxc1lCWE9wVnhkcjNYVzdWTk9QY05OX1RWWFdKOUxFYW52QkpBU1FONE5OdzRBTzFSUFByZVVoVUlJbjk1WGZZazhxaEZQSlI4ZXNqSDZUb0Z0RFJXUEZQbHU5Z21uOTgzbGc?oc=5", "source_name": "Investing News Network", "published_at": "2025-09-12T07:27:26+00:00", "published_display": "12 Sep 2025 07:27", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharmacyte Biotech (PMCB) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1raVRUZ3BhdTNrUXBpVUQ0OEhJM2FtdWR5SUhtb2RoVkhTUFFUU3N6dkZEMUVoZDE2Q2NIbEY3d1lNVmh3YWw1XzJnNXp1RERkVnVN?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:15:22+00:00", "published_display": "25 Apr 2025 00:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Femasys secures nearly $7M in funding from PharmaCyte", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPMXRkUVp0OEp4bGVQcmJUUFN2Rkc1aElGMUhaejNTVjlIdjdGVEVjM0l5ejhXNnZMcDBwbTNNcG1QZlZhYURvOEQ1cGNOaURhRC1Wd2pOVktneGk3TS10VWkyN3owaEtCV2toeXJ5dGlmRTczZHg3cnFFTEUzVTdta0I5VklDZE0?oc=5", "source_name": "MassDevice", "published_at": "2023-11-15T08:00:00+00:00", "published_display": "15 Nov 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmaCyte Biotech Inc (PMCB) Share Price Today | PharmaCyte Biotech Inc (PMCB) Live NSE/BSE", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQbE9sZmpzRVNOb0EyZWpXMkZZUzQxMnBQVWNMRzV6WTBaZ3JiSUZ5RjdZQl96dEdUZEpDOW94Y0gydnoyRFBqb1h0Nmo3Wngwek1zZ1RSSmM4WC1kNmd6SFBKeEljZnl0WmxJdEk2b0p5VW13WnhvTGdsckpLQzFPanQxZWU?oc=5", "source_name": "Value Research", "published_at": "2023-01-11T15:04:52+00:00", "published_display": "11 Jan 2023 15:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After Nasdaq Uplisting, PharmaCyte Biotech Looks Ready to Rumble", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOMmtZUmVXb1BuOXhBSUtkWmNoaDJwUE9LdTVBUE1QS0dfWHJvbVg4dWRiSkZ4UkpqejR0dFVCVXRONS12VUpLbl9uT3gzUTVLRnA4eHplSmVxbzZ5bmd6SnJLa2x4ZHRUeEExdmJrbG5BZ1Nadk82X1Z1aFVyRzJSMDVKb2Q2NlNpZzlxQ0pwWV9DUzFEaFNFdDdnNWJLZy1aSlJRNURJdXRpdw?oc=5", "source_name": "entrepreneur.com", "published_at": "2021-09-07T07:00:00+00:00", "published_display": "07 Sep 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMCB Stock Price and Chart \u2014 NASDAQ:PMCB", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1kR0tzbEZqR19pVEM3Q0tYWFUtV2FONmxlclhZVnNHUnpEZEVEMVA0Q3dxVlJ5a1dpNVU2Tm9UanJLMmh4N3NlelVUMjQ2N2xNOS1sNVg3ZU9jMXhR?oc=5", "source_name": "TradingView", "published_at": "2021-08-11T00:30:46+00:00", "published_display": "11 Aug 2021 00:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharmacyte Biotech (PMCB) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE84dHpsSFI5MU9IOGVuUXhWaElSb0hxNnVuVXZ2TUxRVF9uN1Q4SDdydXhBX2F2RHk1NDFQUGNuQTVHYTRqZm96Q0VPVGZwZw?oc=5", "source_name": "Stock Titan", "published_at": "2020-12-14T15:48:52+00:00", "published_display": "14 Dec 2020 15:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 51, "sentiment_summary": {"positive": 6, "negative": 8, "neutral": 37, "score": 48, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 17.95, "count": 32}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 13}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "capital_return", "label": "Capital return", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 6, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 0.7, "latest_week": "2026-07-10", "one_week_move": -2.6, "four_week_move": -8.5, "twelve_week_move": -4.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.254299, "market_dynamics_buy_signal": false, "relative_strength": -28.905667, "fair_value_gap": -54.5, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 41.9807, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.6% over one week, -8.5% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "TradingKey", "count": 9}, {"label": "TradingView", "count": 6}, {"label": "Market source", "count": 5}, {"label": "dars.gov.et", "count": 4}, {"label": "Moomoo", "count": 2}, {"label": "Intellectia AI", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 32}, {"label": "Earnings", "count": 13}, {"label": "Regulatory and legal", "count": 3}, {"label": "Capital return", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.6% over one week, -8.5% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "PharmaCyte Biotech (PMCB) Holds Near Support as Modest Decline Tests Trader Conviction - Gap Down Bounce Plays"}], "updated_at": "2026-07-16T03:30:13.137573+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}